Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
$7.81
$7.81
$4.06
$9.16
N/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$9.12
$9.20
$4.30
$13.66
$458.93M1.531.18 million shsN/A
Kadmon Holdings Inc stock logo
KDMN
Kadmon
$9.50
$9.50
$3.19
$9.50
$1.70BN/A5.11 million shs1,052 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.87
-2.6%
$2.23
$1.86
$4.73
$21.56M1.0321,127 shs10,553 shs
Vectura Group plc stock logo
VEGPF
Vectura Group
$1.77
$1.77
$1.64
$2.74
$1.07B0.372,185 shsN/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
0.00%0.00%0.00%0.00%0.00%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%0.00%0.00%0.00%0.00%
Kadmon Holdings Inc stock logo
KDMN
Kadmon
0.00%0.00%0.00%0.00%0.00%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-2.60%-1.58%-16.89%-17.62%-47.03%
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.3021 of 5 stars
0.00.00.04.30.01.70.6
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/A
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M5.36N/AN/A($0.34) per share-26.82
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.59N/AN/A$2.77 per share0.68
Vectura Group plc stock logo
VEGPF
Vectura Group
$244.76M4.37$0.28 per share6.33$1.16 per share1.53

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/A0.00N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)
Vectura Group plc stock logo
VEGPF
Vectura Group
$157.16M$0.266.8117.70N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
N/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
90.01%
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%
Vectura Group plc stock logo
VEGPF
Vectura Group
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Emisphere Technologies, Inc. stock logo
EMIS
Emisphere Technologies
6N/AN/ANot Optionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionOptionable
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/A178.52 millionN/AOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable
Vectura Group plc stock logo
VEGPF
Vectura Group
502604.26 millionN/ANot Optionable

TXMD, VEGPF, EMIS, FLXN, and KDMN Headlines

SourceHeadline
Critical Review: Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF)Critical Review: Agios Pharmaceuticals (NASDAQ:AGIO) and Vectura Group (OTCMKTS:VEGPF)
americanbankingnews.com - April 20 at 1:26 AM
European Stocks See Mixed Session as U.K.s FTSE LeadsEuropean Stocks See Mixed Session as U.K.'s FTSE Leads
thestreet.com - January 16 at 11:20 PM
VECTURA GROUP LS -,000271 (V4TA.BE)VECTURA GROUP LS -,000271 (V4TA.BE)
finance.yahoo.com - January 15 at 2:59 PM
Vectura Group PLC (V4TA.BE)Vectura Group PLC (V4TA.BE)
finance.yahoo.com - January 9 at 10:12 AM
Results for Vectura-Fertin PharmaResults for 'Vectura-Fertin Pharma'
afaqs.com - October 11 at 7:33 PM
Vectura Group (OTC:VEGPF), Short Interest ReportVectura Group (OTC:VEGPF), Short Interest Report
benzinga.com - July 18 at 11:14 PM
Carlyle stays in race for VecturaCarlyle stays in race for Vectura
uk.finance.yahoo.com - August 27 at 12:54 PM
Form 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826Form 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826
finance.yahoo.com - August 27 at 6:38 AM
Philip Morris chief attacks critics as Vectura bid tests investorsPhilip Morris chief attacks critics as Vectura bid tests investors
uk.finance.yahoo.com - August 20 at 2:24 AM
Markets: FTSE inches to new post-pandemic high as Vectura takeover draws closerMarkets: FTSE inches to new post-pandemic high as Vectura takeover draws closer
uk.finance.yahoo.com - August 13 at 4:18 AM
Vectura auction called off after Carlyle declines to beat Philip Morris bidVectura auction called off after Carlyle declines to beat Philip Morris bid
uk.finance.yahoo.com - August 10 at 3:02 PM
UPDATE 1-Vectura takeover battle could slip into auction - UK regulatorUPDATE 1-Vectura takeover battle could slip into auction - UK regulator
finance.yahoo.com - August 9 at 8:04 AM
Philip Morris, Carlyle could fight it out for UKs Vectura in auction ringPhilip Morris, Carlyle could fight it out for UK's Vectura in auction ring
ca.finance.yahoo.com - August 9 at 8:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Emisphere Technologies logo

Emisphere Technologies

OTCMKTS:EMIS
Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.
Flexion Therapeutics logo

Flexion Therapeutics

NASDAQ:FLXN
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
Kadmon logo

Kadmon

NYSE:KDMN
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Vectura Group logo

Vectura Group

OTCMKTS:VEGPF
Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.